Pre-Transplant Donor Screening. Viral Load.
Genotyping. Drug Resistance.
| Test Name | Test Code | CPT Code(s) | Specimen Type | NY Approved? | Volume | Turnaround Time |
| HIV-1 Quantitative NAAT | 33259 | 87536 | Plasma | Yes |
2 mL (min. 1.5 mL) |
7 business days from receipt of specimen |
| HIV-1/HIV-2 Plus O EIA | 30816 | 86703 | Plasma, Serum | Yes |
300 µL (min 150 µL) |
Within 24 hours from receipt of specimen
|
| Ultrio Elite HIV-1/2, HCV, HBV NAT | 30805 | 87516, 87521, 87535 | Plasma, Serum | Yes |
2.5 mL (min 1.5 mL) |
|
| HIV-1 Genotypic Drug Resistance Sequencing | 1901 | 87901, 87906 | Plasma | Yes |
2 mL (min. 1 mL/ min. viral load 600 copies/mL) |
4-6 business days from receipt of specimen
|
| HIV-1 Integrase Genotyping | 1950 | 87906 | Plasma | Yes |
SPOTLIGHT ON HIV GENOTYPING & DRUG RESISTANCE
Our HIV-1 Genotypic Drug Resistance Sequencing assay provides the fastest characterization—including subtype identification—of the most relevant viral genomic mutations known to confer resistance to antiretroviral drugs. LEARN MORE
Significant Advantages of Genotyping
- Detects the genomic mutations known to confer resistance to antiretroviral drugs
- Estimates susceptibility to a growing list of approved medications referenced by the preeminent, curated Stanford University HIV Drug Resistance Database (HIVDB)
- Excludes distracting test results (often included in alternative tests) that are unrelated to HIV drug resistance
- Delivers industry-leading turnaround time: <6 days from specimen receipt
- Reduces delays in getting patients on appropriate medications
- Is available via HL7 interface for efficient, streamlined reporting and convenient access to actionable information
- Identifies HIV-1 subtypes B, A, AE, AG, C, D and G
- Is cost-effective
When to Order HIV-1 Genotypic Drug Resistance Sequencing
Because HIV drug resistance changes over time, it is recommended that HIV testing be ordered at various stages in a patient’s journey. Consistent with NIH Guidelines, HIV testing is informative in:
- Getting a baseline profile identifying current viral load
- Problem-solving lack of response to therapy
- Understanding patient deterioration
- Getting clarification when considering a change in drug therapies
Know Your Patient's Susceptibility to Approved Antiretroviral Drugs
Genotyping estimates a patient’s susceptibility to:
- NRTIs
- NNRTIs
- PIs
- INIs
Why Advanced Subtyping Makes Our HIV Testing Most Beneficial
As new HIV strains continue to emerge* in a virus with high genetic variability, Eurofins Viracor fulfills an unmet need for HIV-1 subtyping.
- The Genotyping test reports HIV-1 and provides susceptibility estimates for these subtypes:
- B, A, AE, AG, C, D and G - Alternative tests may estimate only HIV-1 B or may not identify the subtype at all
- B subtype is most common, but 90% of cases worldwide are non-B
- Non-B is on the rise in the US
- As non-B prevalence rises, the assay will deliver a growing body of knowledge about treatment
*https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2614444/
The Stanford University HIV Database Assures Testing is Current on Approved HIV Antiretroviral Drugs
A patient’s susceptibility profile is determined by Eurofins Viracor HIV-1 Genotypic Drug Resistant Sequencing test, based on the curated Stanford University HIV Drug Resistance Database. For a complete list of regions evaluated, associated susceptibility, and references, visit: https://hivdb.stanford.edu/pages/references.html.
Advantages include:
- The Stanford database lists possible mutations and also includes links to supporting literature
- Stanford updates the database continually. Viracor incorporates the newest updates in its reporting. Physicians receive reports based on current, curated data to support drug therapy decisions
- The database stores, analyzes, and makes publicly available HIV drug resistance data from HIV researchers and clinicians
- Stanford helps identify gaps in drug resistance information and updates its information through retrospective or prospective studies
- Other HIV drug resistance testing may use only a lab-developed algorithm
| Type of Drug | Drugs Reported |
| Nucleoside Reverse-Transcriptase Inhibitors (NRTI) |
Abacavir (ABC), Zidovudine (AZT), Stavudine (D4T), Didanosine (DDI), Emtricitabine (FTC), Lamivudine (3TC), Tenofovir (TDF) |
| Non-Nucleoside Reverse-Transcriptase Inhibitors (NNRTI) |
Doravirine (DOR), Efavirenz (EFV), Etravirine (ETR), Nevirapine (NVP), Rilpivirine (RPV) |
| Protease Inhibitors (PI) |
Atazanavir w/ritonavir (ATV/r), Darunavir w/ritonavir (DRV/r), Fosamprenavir w/ritonavir (FPV/r), Indinavir w/ritonavir (IDV/r), Lopinavir w/ritonavir (LPV/r), Nelfinavir (NFV), Saquinavir w/ritonavir (SQV/r), Tipranavir w/ritonavir (TPV/r) |
| Integrase Inhibitors (INI) |
Bictegravir (BIC), Dolutegravir (DTG), Elvitegravir (EVG), Raltegravir (RAL) |